Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis
- 1 February 2016
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (2) , 1091-1096
Abstract
Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections. We recently described the reduced activity of PZA in C3HeB/FeJ mice with large caseous tubercles due to neutral pH. Here, we aimed to determine the contribution of PZA to the sterilizing activity of the first-line TB regimen in C3HeB/FeJ and BALB/c mice. Three regimens were compared (in combinations: R, rifampin; H, isoniazid; E, ethambutol; Z, pyrazinamide; with numbers indicating the treatment duration, in months): 2RHEZ/4RH, 2RHE/4RH, and 2RHEZ/4RHZ. Lung CFU counts were assessed after 0 and 2 months of treatment, and relapse rates were assessed 3 months after 3, 4.5, and 6 months of treatment. The relapse rates after 3 months of treatment were 53% and 95% in C3HeB/FeJ mice receiving 2RHEZ/1RH and 2RHE/1RH, respectively, and 67%, 100%, and 80% in BALB/c receiving 2RHEZ/1RH, 2RHE/1RH, and 2RHEZ/1RHZ, respectively. The relapse rates after 4.5 months of treatment were 32%, 20%, and 0% in C3HeB/FeJ mice receiving 2RHEZ/2.5RH, 2RHE/2.5RH, and 2RHEZ/2.5RHZ, respectively, and 0% and 67% in BALB/c receiving 2RHEZ/2.5RH and 2RHE/2.5RH, respectively. The month-6 relapse rates were 0%, 13%, and 0% in C3HeB/FeJ mice given 2RHEZ/4RH, 2RHE/4RH, and 2RHEZ/4RHZ, respectively, and 7% in BALB/c mice receiving 2RHE/4RH. The addition of PZA shortens the duration of treatment needed to prevent relapse in both mouse strains. However, while its contribution is limited to the first 2 months of treatment in BALB/c mice, continuing PZA beyond the first 2 months is beneficial in C3HeB/FeJ mice by preventing relapse among those with the highest disease burden.Keywords
Funding Information
- HHS | National Institutes of Health (R01-AI111992)
- Bill and Melinda Gates Foundation (OPP1037174)
This publication has 21 references indexed in Scilit:
- Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Pyrazinamide pharmacokinetics and efficacy in adults and childrenTuberculosis, 2012
- Noninvasive Pulmonary [ 18 F]-2-Fluoro-Deoxy- d -Glucose Positron Emission Tomography Correlates with Bactericidal Activity of Tuberculosis Drug TreatmentAntimicrobial Agents and Chemotherapy, 2009
- Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis DrugsAntimicrobial Agents and Chemotherapy, 2009
- Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 DaysAmerican Journal of Respiratory and Critical Care Medicine, 2003
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].1982
- Whither short-course chemotherapy?Respiratory Medicine, 1981